FRANKLIN LAKES, N.J., July 19, 2011 /PRNewswire/ -- Oncology treatments are not what they were a decade ago.  Drugs that target specific molecular pathways in a cancer cell are being added to or replacing once standard therapies, requiring a new model of patient care.  Medco Health Solutions, Inc. (NYSE: MHS) today announced new offerings within its Advanced Oncology Solutions™, that include treatment pathways decision support with embedded pharmacogenomic testing and nutrition recommendations for cancer patients.


Treatment Pathway Connections is the newest component in Medco's Advanced Oncology Solution's platform, which coordinates care among physicians, pharmacists, case managers and payers, and informs them of evidence-based protocols before and during treatment.  eviti®, a web-based oncology decision-support program developed by ITA Partners, Inc.®, will power the treatment plan decision-support function of the platform.

"Through eviti, our treatment pathway program is able to align quality care with reimbursement, reduce complexity, provide transparency and improve workflows for physicians and payers," said Jeff Ulanet, vice president oncology.  "Our goal is to reduce the gaps in care that negatively impact patient outcomes and can lead to unnecessary treatment costs."

Medco is the first PBM to offer this independent, comprehensive oncology decision support approach that contains more than 1,000 evidence based treatment regimens for more than 120 cancer types, displaying efficacy, costs, toxicity and compliance with the patient's plan language – all at the moment of prescribing.  ITA Partners, which employs a team of oncologists, oncology nurses, insurance professionals, actuaries, software designers and engineers has specialized in oncology de